TWD 91.2
(0.0%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | -191.81 Million TWD | -77.17% |
2022 | -108.26 Million TWD | -85.85% |
2021 | -58.25 Million TWD | -288.49% |
2020 | 30.9 Million TWD | -71.8% |
2019 | 109.57 Million TWD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | -298.59 Million TWD | -55.67% |
2024 Q2 | -307.64 Million TWD | 1.06% |
2023 Q3 | -238.37 Million TWD | -33.15% |
2023 Q4 | -191.81 Million TWD | 19.53% |
2023 FY | -191.81 Million TWD | -77.17% |
2023 Q2 | -179.02 Million TWD | 21.19% |
2023 Q1 | -227.15 Million TWD | -109.82% |
2022 Q3 | -141.9 Million TWD | 0.0% |
2022 Q4 | -108.26 Million TWD | 23.71% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Allied Biotech Corporation | 178.11 Million TWD | 207.69% |
GeneFerm Biotechnology Co., Ltd. | 31.92 Million TWD | 700.796% |
Easywell Biomedicals, Inc. | 123.43 Million TWD | 255.391% |
TTY Biopharm Company Limited | -705.97 Million TWD | 72.831% |
Synmosa Biopharma Corporation | 1.52 Billion TWD | 112.608% |
Orient EuroPharma Co., Ltd. | 3.1 Billion TWD | 106.175% |
Center Laboratories, Inc. | 3.91 Billion TWD | 104.894% |
Tien Liang BioTech Co., Ltd. | -57.55 Million TWD | -233.258% |
Orient Pharma Co., Ltd. | 633.6 Million TWD | 130.273% |
InnoPharmax Inc. | -17.85 Million TWD | -974.084% |
Johnson Chemical Pharmaceutical Works Co., Ltd. | -926.77 Million TWD | 79.304% |
Excelsior Biopharma Inc. | -212.51 Million TWD | 9.742% |
DV Biomed Co., Ltd. | 160.7 Million TWD | 219.359% |
Foresee Pharmaceuticals Co., Ltd. | -781.42 Million TWD | 75.454% |
Handa Pharmaceuticals, Inc. | -653.8 Million TWD | 70.663% |
UniPharma Co., Ltd. | -68.36 Million TWD | -180.559% |
Anxo Pharmaceutical Co., Ltd. | 492.4 Million TWD | 138.954% |
Alar Pharmaceuticals Inc. | -738.05 Million TWD | 74.011% |
Mercury Biopharmaceutical Corporation | -1.94 Million TWD | -9761.697% |
Bioray Biotech Co., Ltd | -27.23 Million TWD | -604.355% |
TSH Biopharm Corporation Limited | -568.74 Million TWD | 66.275% |